Loading...

CYTK CYTOKINETICS INC Product Launches 8-K Filing

CYTK

CYTK

CYTOKINETICS INC

(CYTK)

2026 8-K

Financial Results Revealed

EU Approval Update

FDA Approval Announced

Positive Opinion Received

Management Change

Financial Results Update

Convertible Note Offering

Regulatory Update

Data Presentation

Data Presentation Update

Clinical Trial Results

Board Appointment

Financial Statements

Financial Statements

New Drug Application Review

Regulatory Update

Financial Results

Director Appointment

Management Changes

License Agreement

Board Resignation

Management Appointment

Financial Results Announcement

Exercise of Option to Purch...

President's Address

Public Offering

Loan Agreement Amendment an...

Resignation and Stock Purch...

Earnings Reports

Financial Results for Q1 2024

Clinical Trial Announcement

Phase 1 Study Results

Clinical Study Data

Financial Results Announcement

Resignation of CFO

Positive Clinical Trial Res...

Bylaws Amendment

Earnings Report

Clinical Trial Results

Departure of Directors or C...

Earnings Reports

Phase 1 Clinical Study Init...

Annual Meeting of Stockholders

Financial Results Announcement

Discontinuation of Phase 3 ...

Clinical Trial Results

Financial Results Announcement

Compensation & Talent Commi...

Bylaws Amendment

Regulation FD Disclosure

External Links:

Cytokinetics Inc. announced that as of February 17, 2026, the European Commission approved their drug MYQORZO® for treating obstructive hypertrophic cardiomyopathy in adults, available in 5 mg, 10 mg, 15 mg, and 20 mg doses.

AI Assistant

CYTOKINETICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.